# A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

> **NCT02930109** · PHASE1,PHASE2 · COMPLETED · sponsor: **Prescient Therapeutics, Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Acute Leukemia

## Interventions

- **DRUG:** PTX-200
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02930109
- **Lead sponsor:** Prescient Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-09
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-03-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930109, "A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02930109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*